Get the Stockscreener App
1.4401
3.93%
-0.0599
MAIA Biotechnology Inc stock is traded at $1.4401, with a volume of 116.36K.
It is down -3.93% in the last 24 hours and down -11.05% over the past month.
MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer. It is also developing second generation telomere targeting agents. MAIA Biotechnology, Inc. was incorporated in 2018 and is headquartered in Chicago, Illinois.
See More
Previous Close:
$1.50
Open:
$1.5
24h Volume:
116.36K
Relative Volume:
0.20
Market Cap:
$47.84M
Revenue:
-
Net Income/Loss:
$-25.94M
P/E Ratio:
-1.0436
EPS:
-1.38
Net Cash Flow:
$-15.79M
1W Performance:
+5.96%
1M Performance:
-11.05%
6M Performance:
-22.53%
1Y Performance:
-42.59%
1-Day Range:
$1.44
$1.50
1-Week Range:
$1.33
$1.57
52-Week Range:
$1.2602
$3.48
MAIA Biotechnology Inc Stock (MAIA) Company Profile
Name
MAIA Biotechnology Inc
Sector
Industry
Phone
312 416 8592
Address
444 West Lake Street, Suite 1700, Chicago
Compare MAIA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MAIA
MAIA Biotechnology Inc
|
1.45 | 49.49M | 0 | -25.94M | -15.79M | -1.38 |
|
VRTX
Vertex Pharmaceuticals Inc
|
419.86 | 107.73B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
637.17 | 62.04B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
476.65 | 62.73B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
ARGX
Argen X Se Adr
|
833.61 | 51.09B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
164.95 | 34.67B | 398.11M | -1.03B | -868.57M | -5.7032 |
MAIA Biotechnology Inc Stock (MAIA) Latest News
Is MAIA Biotechnology Inc. stock among top earnings playsMarket Trend Review & Fast Exit Strategy with Risk Control - newser.com
Analyzing drawdowns of MAIA Biotechnology Inc. with statistical toolsJuly 2025 Momentum & Risk Controlled Swing Trade Alerts - newser.com
Why MAIA Biotechnology Inc. is moving today2025 Dividend Review & Free Real-Time Market Sentiment Alerts - newser.com
Can swing trading help recover from MAIA Biotechnology Inc. lossesJuly 2025 Breakouts & Fast Entry Momentum Alerts - newser.com
Will MAIA Biotechnology Inc. stock see PE expansion2025 Biggest Moves & Smart Money Movement Tracker - newser.com
Does MAIA Biotechnology Inc. show high probability of rebound2025 Geopolitical Influence & Detailed Earnings Play Alerts - newser.com
Published on: 2025-10-28 02:40:21 - newser.com
How high can MAIA Biotechnology Inc. stock goSell Signal & Long-Term Safe Investment Ideas - newser.com
Is MAIA Biotechnology Inc. stock bottoming outWeekly Trade Recap & Risk Controlled Swing Trade Alerts - newser.com
How strong is MAIA Biotechnology Inc. stock balance sheetJuly 2025 Sector Moves & Stepwise Entry and Exit Trade Signals - newser.com
Applying sector rotation models to MAIA Biotechnology Inc.July 2025 Opening Moves & Consistent Income Trade Ideas - newser.com
Is MAIA Biotechnology Inc. stock prepared for digital transition2025 Fundamental Recap & Verified Short-Term Plans - newser.com
MAIA Biotechnology Presents at 2025 Cancer Conference - TipRanks
MAIA Biotechnology’s Phase III Study: A New Hope for Advanced NSCLC Treatment - TipRanks
Predicting MAIA Biotechnology Inc. trend using moving averagesJuly 2025 Breakouts & AI Driven Stock Price Forecasts - newser.com
MAIA Biotechnology’s Innovative Approach in NSCLC Treatment: A Phase 2 Study Update - TipRanks
What drives MAIA Biotechnology Inc stock priceBullish Engulfing Patterns & Receive Monthly Expert Trading Blueprints - earlytimes.in
MAIA Biotechnology Presents Trial in Progress Poster at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - The Manila Times
MAIA (NYSE American: MAIA) presents THIO-101 poster; 5 enrolled in Part C Taiwan, Turkey - Stock Titan
MAIA Biotechnology Showcases Promising Cancer Trial Results - MSN
MAIA Biotechnology, Inc Presents Phase 2 Study Results - TradingView
MAIA Biotechnology Inc Stock (MAIA) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.12%
0.55%
Cap:
|
Volume (24h):